[1] |
HUANG Cuili, GAO Ao, WANG Jiaxi, GUO Haili, XU Xiaohan, CHENG Yinchu, GUO Daihong.
Automatic monitoring and assessment of antibiotics-related thrombocytopenia
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 807-811.
|
[2] |
LI Rongrong, LI Meng, GOU Yue, LUO Qiong, LYU Hua, SUN Xin, LIU Chenghai.
Clinical characteristics and risk factors of 113 cases of anti-neoplastic drug-induced liver injury
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 505-510.
|
[3] |
LYU Peng, ZHANG Jingli, WANG Yunhong, MA Fenfen, ZHANG Yu, HUANG Yifei.
Risk factors and mechanisms for skin squamous cell carcinoma in lung transplant recipients induced by voriconazole
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 595-600.
|
[4] |
WANG Jiaxi, GUO Daihong, ZHANG Bo, Li Boyan, GUO Haili.
Automatic monitoring and risk factors of acute kidney injury in 116097 dosing cases of flurbiprofen axetil
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 201-205.
|
[5] |
WANG Li, YU Wenwen, LI Min, GUO Ruihui, CAO Guangsheng, QI Yingmei.
Risk factors and precautions for adverse drug reactions caused by Digoxin
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1269-1272.
|
[6] |
YAO Xin, GE Qiuge, LI Yamin, WANG Yifan, LI Yuanyuan, LIU Zhiqiang.
Adverse drug reactions caused by new anti-tumor drugs from 2018 to 2022 in one hospital
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1273-1278.
|
[7] |
YU Min, LI Xin.
Immunerelated adverse events and risk factors of carrelizumab in 528 cases of cancer patients
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1134-1140.
|
[8] |
ZHANG Jingyu, ZHANG Yuanyuan, WANG Jing, MA Bo, LI Wenjuan.
Influencing factors of severe anaphylactic reactions of Yanhuning injections in children
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(9): 1019-1022.
|
[9] |
CHEN Congcong, TAN Ruijuan, WANG Lidan, ZHANG Yuanyuan, HU Xiaoyan, CHEN Yuanyuan.
Clinical characteristics and risk factors of thrombocytopenia induced by fluoroquinolones
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(3): 306-309.
|
[10] |
LI Boyan, GUO Daihong, ZHU Yu, WANG Jiaxi, ZHANG Bo, GUO Haili.
Automatic monitoring of thrombocytopenia caused by bevacizumab in 4 864 inpatients and related influencing factors
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(12): 1362-1367.
|
[11] |
LIN Yanfang, SU Songsen, ZHOU Hong, CAI Lili, HONG Lei, LIN Zhiqiang.
Tentative Study of Risk Factors of Hematological Toxicity Induced by Azathioprine
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(8): 461-464.
|
[12] |
TU Can, GE Feilin, GUO Yuming, ZHANG Yaming, XIAO Xiaohe, WANG Jiabo.
Analysis of Clinical Characteristics and Medication Rationality of Polygonum Multiflorum Thunb. and Its Preparation-related Liver Injury
[J]. Chinese Journal of Pharmacovigilance, 2019, 16(5): 270-276.
|
[13] |
YU Hongli, YU Dongmei, SONG Haibo, REN Jingtian.
Literature Study on Adverse Drug Reactions and Analysis of Risk Factors of Polygonum multiflorum Thunb. and its Common Preparations
[J]. Chinese Journal of Pharmacovigilance, 2018, 15(8): 470-475.
|
[14] |
ZHENG Li-jia, ZHAO Yan, DONG Fang.
Medical Device Adverse Events Monitoring and Risk Analysis on Ventilators
[J]. Chinese Journal of Pharmacovigilance, 2016, 13(8): 503-504.
|
[15] |
YU You-jian.
Effect of Fluoride Foam Applied to Early Childhood Caries and Risk Analysis
[J]. Chinese Journal of Pharmacovigilance, 2016, 13(10): 619-622.
|